Eye Patching for Intermittent Exotropia

(IXT7 Trial)

No longer recruiting at 28 trial locations
RT
KM
Overseen ByKatie M Stutz
Age: < 18
Sex: Any
Trial Phase: Phase 3
Sponsor: Jaeb Center for Health Research
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if full-time patching of one eye (Full-Time Occlusion Therapy) is more effective than observation alone in improving control of intermittent exotropia, a condition where one eye occasionally turns outward. Participants will either wear a patch on one eye during all waking hours or be observed without additional treatment for three months. Children diagnosed with intermittent exotropia by a pediatric eye specialist and who wear glasses as needed may be suitable for this study. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants the opportunity to contribute to a treatment nearing widespread availability.

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications. It is best to discuss this with the trial coordinators or your doctor.

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. It mainly focuses on eye conditions and treatments related to intermittent exotropia.

Is there any evidence suggesting that Full-Time Occlusion Therapy is likely to be safe for humans?

Research has shown that wearing an eye patch all day, known as full-time patching, is generally well-tolerated by children with intermittent exotropia (IXT), a condition where the eyes occasionally drift outward. Studies comparing patching to no treatment have found both options reasonable for managing IXT in children aged 3 to 10 years.

No evidence links full-time patching to serious side effects. While wearing a patch for extended periods might cause minor discomfort or irritation, these issues are usually not severe. The safety of patching is sufficient for it to be often recommended as a standard treatment for IXT.12345

Why do researchers think this study treatment might be promising?

Researchers are excited about the full-time occlusion therapy for intermittent exotropia because it offers a non-surgical approach that could provide significant benefits. Unlike the standard of care, which often involves surgery or part-time patching, this method involves daily, alternate eye patching for all waking hours, potentially improving eye alignment and control without invasive procedures. This approach allows the eyes to work together more effectively, offering a promising alternative for managing the condition with a simple, yet rigorous regimen.

What evidence suggests that full-time occlusion therapy is effective for intermittent exotropia?

This trial will compare full-time patching with observation for managing intermittent exotropia (IXT). Studies have shown that wearing an eye patch full-time can help manage IXT, a condition where the eyes sometimes drift outward. Research suggests that this treatment can improve how well the eyes work together, even if it doesn't change the angle at which the eyes drift. Some studies indicate that wearing a patch all day, alternating eyes each day, might be more effective than just monitoring the condition. These findings support the potential benefits of full-time patching in managing IXT.12467

Who Is on the Research Team?

EC

Erin C Jenewein, OD

Principal Investigator

Salus University

SP

Stephen P Christiansen, MD

Principal Investigator

Boston Children's Hospital

Are You a Good Fit for This Trial?

This trial is for children aged 3 to under 9 with intermittent exotropia, a type of eye misalignment. They must have worn corrective glasses if needed, be in good health otherwise, and not planning to move away soon. Kids who've had previous eye surgeries or treatments for this condition, severe developmental delays, or allergies to adhesive patches can't join.

Inclusion Criteria

Patient and/or parent understands protocol, is willing to enroll, and is willing to accept that other (i.e., nonrandomized) treatment for IXT will not be offered by the investigator for 3 months
Birth weight > 1500 grams
My child, aged 3-8, sees a children's eye doctor.
See 4 more

Exclusion Criteria

My vision is good except for needing glasses or contacts.
Severe developmental delay that would interfere with treatment or evaluation
Known allergy to silicone
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive full-time patching (all waking hours) for 3 months or are observed without treatment

3 months
Daily monitoring by caregivers, primary outcome visit at 3 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Full-Time Occlusion Therapy
Trial Overview The study tests if wearing an eye patch full-time helps improve the control of intermittent exotropia over three months better than just watching the condition without treatment. The effectiveness will be compared after the treatment period.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Full Time PatchingExperimental Treatment1 Intervention
Group II: Observation GroupActive Control1 Intervention

Full-Time Occlusion Therapy is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Full-Time Occlusion Therapy for:
🇪🇺
Approved in European Union as Full-Time Occlusion Therapy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Jaeb Center for Health Research

Lead Sponsor

Trials
162
Recruited
36,200+

National Eye Institute (NEI)

Collaborator

Trials
572
Recruited
1,320,000+

Pediatric Eye Disease Investigator Group

Collaborator

Trials
20
Recruited
4,800+

Published Research Related to This Trial

In a study of 76 children aged 3-8 with intermittent exotropia, alternate part-time patching significantly improved deviation control compared to observation, particularly noted at both near and far distances after 3 and 6 months.
While stereoacuity (the ability to perceive depth) did not show significant differences between the patching and observation groups, the patching group exhibited greater improvements in stereoacuity from baseline, indicating potential benefits beyond just deviation control.
The influence of alternate part-time patching on control of intermittent exotropia: a randomized clinical trial.Akbari, MR., Mehrpour, M., Mirmohammadsadeghi, A.[2021]
In a study involving 358 children aged 3 to <11 years with untreated intermittent exotropia (IXT), part-time patching for 3 hours daily over 5 months resulted in a significantly lower deterioration rate (0.6%) compared to observation (6.1%) after 6 months, indicating its efficacy in preventing worsening of the condition.
Both part-time patching and observation are reasonable management strategies for IXT in children, as deterioration is uncommon in either approach, suggesting that patching may offer a slight advantage in maintaining eye alignment.
A randomized trial comparing part-time patching with observation for children 3 to 10 years of age with intermittent exotropia.Cotter, SA., Mohney, BG., Chandler, DL., et al.[2023]
In a study of 21 untreated children with intermittent exotropia (IXT), occlusion therapy showed that 11% of participants had a significant reduction in their eye deviation angle, while 55.5% improved their fusional amplitudes to normal levels.
The therapy was effective in enhancing sensory status and control of IXT, suggesting it can be a useful non-surgical option to delay surgery and potentially improve surgical outcomes in young children.
Does occlusion therapy improve control in intermittent exotropia?AlKahmous, LS., Al-Saleh, AA.[2020]

Citations

Full-Time Occlusion Therapy for Intermittent Exotropia in ...The purpose of this study is to determine whether full-time patching is more effective than observation for improving distance control of IXT after 3 months of ...
Does occlusion therapy improve control in intermittent ...We suggest that alternate occlusion therapy can improve the sensory status and strengthen the fusional amplitudes but does not improve the deviation angle.
Randomized Trial of Full-Time Occlusion Therapy ...The purpose of this study is to determine whether full-time patching is more effective than observation for improving distance control of IXT ...
Full-Time Occlusion Therapy for Intermittent Exotropia in ...The purpose of this study is to determine whether full-time patching is more effective than observation for improving distance control of Intermittent ...
Non-surgical therapy for intermittent exotropia: a systematic ...This study aimed to conduct a network meta-analysis to evaluate the efficacy of various non-surgical treatments for intermittent exotropia(IXT).
Signature Page Randomized Trial of Full-Time Occlusion ...observation versus part-time patching for intermittent exotropia, limited to 278 participants with. 841 similar baseline age (3 to <9 years) ...
A Randomized Trial Comparing Part-time Patching with ...Although there is a slightly lower deterioration rate with patching, both management approaches are reasonable for treating 3 to 10 year olds with IXT.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security